Travere Therapeutics (TVTX) and CSL Vifor announced that the European Commission has approved the conversion of the conditional marketing approval into a standard marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy with a urine protein excretion of 1.0 g/day. Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere, CSL Vifor announce EC approval of Filspari marketing authorization
- TVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tax Day 2025 IRS Payment: Stocks to Consider Buying With the Refund
- Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
- Travere Therapeutics price target raised to $47 from $45 at Canaccord